Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials.
暂无分享,去创建一个
G. Hindricks | H. Heidbuchel | T. Potpara | M. Valgimigli | J. Collet | N. Dagres | G. Lip | M. Proietti | Nebojša M. Mujović | Marco Proietti | N. Mujović
[1] Deepak L. Bhatt,et al. Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials. , 2019, JAMA cardiology.
[2] M. Price,et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk , 2019, European heart journal.
[3] A. Parkhomenko,et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation , 2019, The New England journal of medicine.
[4] Deepak L. Bhatt,et al. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial , 2019, European heart journal.
[5] M. Valgimigli,et al. Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention? , 2018, European heart journal.
[6] Deepak L. Bhatt,et al. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials , 2018, European heart journal.
[7] Deepak L. Bhatt,et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation , 2017, The New England journal of medicine.
[8] Xiaoxi Yao,et al. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. , 2017, Journal of the American College of Cardiology.
[9] G. Lip,et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. , 2016, The New England journal of medicine.
[10] H. Schunkert,et al. Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. , 2015, Journal of the American College of Cardiology.
[11] Tom Adriaenssens,et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial , 2013, The Lancet.
[12] Fredrik Folke,et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. , 2010, Archives of internal medicine.